Business
Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne
NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 (TLR2), one of the most critical pathways for acne pathophysiology. The study also showed that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are also relevant therapeutic markers for other inflammatory-driven skin diseases.\n\n \n \n \n \n \n \n\n \nHT-003 is a group of retinoic acid metabolism blocking agents (RAMBA), which are novel agents that prevent the breakdown of retinoic acid. Retinoic acid acts as an anti-inflammatory agent in the body. \nAs part of the study, mouse skin was topically pre-treated with RAMBA or a non-clinical vehicle for two days. Then, the skin was intradermally injected peptidoglycan (PGN), which induces acne-like inflammation. The models demonstrated that PGN-induction of TLR2 and a broad list of inflammatory cytokines were inhibited in skin pre-treated with RAMBA.\n\"The results of this study are extremely promising and suggests that this drug could both treat acne and may actually help prevent it,\" said Dr. Jonathan Zippin, M.D., Ph.D., FAAD, Associate Professor of Dermatology at Weill Cornell Medicine and Hoth Senior Scientific Advisor, who is lead on the study. \"The data also suggests that the HT-003 compounds have the potential for treatment of numerous inflammatory skin diseases.\"\nIn addition to the dermatologic application, Hoth Therapeutics is exploring the potential application of HT-003 assets in inflammatory bowel disorders (IBDs).\nAbout Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, pleas...